Drug intelligence / Profile preview

ZEN-3365

Development stage: Discontinued
Lead developer: Zenith Epigenetics
Modality: Small Molecules
Administration: Oral

Overview

ZEN-3365 (also known as ZEN003365) is a small molecule inhibitor targeting BET proteins (Bromodomain and Extra-Terminal domain proteins). It was developed by Zenith Epigenetics for the treatment of neoplasms and hematologic malignancies, specifically relapsed or refractory lymphoproliferative malignancies and acute myeloid leukemia. The drug acts as a BET inhibitor, interfering with epigenetic regulation of gene expression involved in cancer cell proliferation. Clinical development reached Phase 1 trials but has since been discontinued[1][2][3].

Targets

BRD2 (Bromodomain-containing protein 2)BRDT (Bromodomain testis-specific protein)BRD3 (Bromodomain-containing protein 3)BRD4 (Bromodomain-containing protein 4)

Beyond the preview

Go deeper on ZEN-3365.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZEN-3365.

Explore the full profile